Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Tre...
June 15 2021 - 8:19AM
Biomerica, Inc. (NASDAQ: BMRA) today announced that the Mexican
Patent Office has issued a notice of allowance for Biomerica’s
patent application pertaining to the Company’s InFoods® technology
platform that offers a revolutionary approach in the treatment of
patients suffering from Irritable Bowel Syndrome (“IBS”).
Specifically, this allowed application contains claims that broadly
cover the method that enables physicians to identify patient
specific foods, such as milk, shrimp, broccoli, etc., that, when
removed from the patient’s diet, may alleviate or improve an
individual’s IBS symptoms, including constipation, diarrhea,
bloating, severe cramping, pain and indigestion.
“We’re excited to have received this allowed patent in Mexico
which provides broad protection around tests and methods used to
determine patient-specific foods that may trigger IBS symptoms, and
includes additional claims that cover a diagnostic-guided therapy
for IBS patients,” said Zack Irani, Chairman and Chief Executive
Officer of Biomerica. “Studies show that food can heighten
inflammation in the body, and we believe the InFoods® technology
can identify patient-specific foods that often trigger IBS
symptoms. This Mexican patent is part of our ongoing international
strategy to protect the intellectual property for our unique IBS
diagnostic guided therapy, and joins recently issued Japanese
patent #6681907, and Korean patent #10-1887545 covering
compositions, devices and methods for IBS sensitivity testing.”
Mr. Irani concluded, “Biomerica has additional international and
U.S. patent applications in prosecution related to the InFoods® IBS
product, as well as multiple applications that cover the use of our
InFoods® Technology in other diseases. In addition, we have filed
digital health patents that cover digital applications that will
assist patients with managing their dietary restrictions as defined
by the InFoods® technology. We believe the allowance of our Mexico
patent further validates the strength of our technology platform
and enhances our efforts to enable physicians to offer new and
better therapies to patients.”
About Biomerica (NASDAQ: BMRA)Biomerica, Inc.
(www.biomerica.com) is a global biomedical technology company that
develops, patents, manufactures and markets advanced diagnostic and
therapeutic products used at the point of care (in home and in
physicians' offices) and in hospital/clinical laboratories for
detection and/or treatment of medical conditions and diseases. The
Company's products are designed to enhance the health and
well-being of people, while reducing total healthcare costs.
Biomerica’s primary focus is on gastrointestinal and inflammatory
diseases where the Company has multiple diagnostic and therapeutic
products in development.About InFoods®The
Biomerica InFoods® IBS product is designed to allow physicians
to identify patient-specific foods (e.g., eggs, broccoli, wheat,
potatoes, pork, etc.), that when removed from the diet, may
alleviate or improve an individual's IBS symptoms including, but
not limited to, constipation, diarrhea, bloating, pain and
indigestion. This patented, diagnostic-guided therapy is designed
to allow for a patient-specific, guided dietary regimen to improve
IBS outcomes. A point-of-care version of the product is being
developed to allow physicians to perform the test in-office using a
finger stick blood sample, while a clinical lab version of the
product is expected to be the first for which the company will seek
regulatory approval. A billable CPT code that can be used by both
clinical labs and physicians' offices is already available for
InFoods® products. Since the InFoods® product is a
diagnostic-guided therapy, and not a drug, it has no drug type side
effects. An estimated 45 million people in America currently suffer
from IBS making it a leading cause for patient doctor visits. 1
Luis Alberto Sánchez-Vargas, Karina Guadalupe Hernández-Flores,
Francisco Javier Cabrera-Jorge, José María Remes-Troche, Job
Reyes-Huerta and Héctor Vivanco-Cid. The Prevalence of Anti-Zein
Antibodies: A Comparative Study between Celiac Disease and
Irritable Bowel Syndrome Nutrients 2021, 13(2), 649.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking, such as
statements relating to the efficacy of the Company’s tests, FDA
clearance of the Company’s products, EUA clearance, the rapidity of
testing results, uniqueness of the Company’s products, test result
accuracy of products, pricing of the Company’s test kits, demand
for domestic or international orders, potential revenues from the
sale of current or future products, availability of the Company’s
test kits, the size of the markets the Company’s products may
address, the degree of protection from competition patents may
provide the Company and actual patent protection on any of the
Company’s products or technologies. Such forward-looking
information involves important risks and uncertainties that could
significantly affect anticipated results in the future, including,
without limitation: results of studies testing the efficacy of the
Company’s tests, including its COVID-19 tests, InFoods tests and
other products; regulatory approvals necessary prior to
commercialization of the Company’s products; availability of the
Company’s test kits and other products; capacity, resource and
other constraints on our suppliers; dependence on our third party
manufacturers; dependence on international shipping carriers;
governmental import/export regulations; demand for our various
tests and other products; competition from other similar products
and from competitors that have significantly more financial and
other resources available to them; governmental virus control
regulations that make it difficult or impossible for the company to
maintain current operations; regulations and regulatory clearance
for the company’s manufacturing facilities and other clearances
needed to manufacture and sell a medical related product, and the
Company’s ability to obtain patent protection on any aspects of its
rapid test technologies or other products. Accordingly, such
results may differ materially from those expressed in any
forward-looking statements made by or on behalf of Biomerica.
Additionally, potential risks and uncertainties include, among
others, fluctuations in the Company's operating results due to
revenue fluctuations, drop in demand for the Company’s products,
changes in its business model and expansion plans, downturns in
international and or national economies, the Company's ability to
raise additional capital, the competitive environment in which the
Company will be competing, and the Company's dependence on
strategic relationships. The Company is under no obligation to
update any forward-looking statements after the date of this
release.
Corporate Contact:
John Nesbett /Jennifer BelodeauIMS Investor
Relations203.972.9200jnesbett@institutionalms.com
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2023 to Apr 2024